hla class ii histocompatibility antigen dr alpha chain  (Cell Signaling Technology Inc)

Journal: iScience

Article Title: Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity

doi: 10.1016/j.isci.2022.105643

Figure Lengend Snippet: Quantification of sHLA class I molecules in COVID-19 patients, SARS-CoV-2 convalescent individuals and healthy donors (A) Soluble HLA class I levels in the serum of COVID-19 (n = 31), Convalescent (n = 290) and Control donors (n = 80). See Figure S3 A for sHLA-DR. (B and C) Longitudinal follow-up analysis of sHLA class I levels in (B) convalescent individuals (n = 53) at different timepoints ( T1 , timepoint 1, 19 - 52 days after positive PCR; T2 , timepoint 2, 141 - 170 days after positive PCR) and (C) compared to healthy control donors ( Control , n = 80). (D) Soluble HLA class I levels in the serum of convalescents with ( persisting symptoms , n = 51) and without ( asymptomatic , n = 11) persistence of symptoms after SARS-CoV-2 infection compared to healthy control donors ( Control , n = 80). (E) Soluble HLA class I serum levels in COVID-19 patients with (n = 4) and without (n = 26) requirement for invasive ventilation. (F) Correlation analysis of sHLA class I levels to SARS-CoV-2-specific T cell response intensities in terms of calculated spot counts in ELISpot assays in convalescent individuals (n = 68). Linear regression line with 95% confidence level (dotted lines), Spearman’s rho (ρ) and p value. Each dot represents the sHLA class I serum level of one donor measured by enzyme-linked immunosorbent assay (ELISA). Boxes represent median and 25 th to 75 th percentiles, whiskers are minimum to maximum. Different symbols represent COVID-19-specific treatment (no treatment, remdesivir, dexamethasone, combined treatment with remdesivir and dexamethasone) for the COVID-19 cohort within three days before sample collection. (A, D) Kruskal-Wallis test, (B) Wilcoxon matched-pairs signed rank test, (C) Mann-Whitney U test comparing T1 or T2 to Control .

Article Snippet: Human HLA Class II Histocompatibility Antigen, DR Alpha Chain (HLA-DRA) ELISA kit , Cusabio , Cat# CSB-EL010497HU.

Techniques: Control, Infection, Enzyme-linked Immunospot, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY

Journal: iScience

Article Title: Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity

doi: 10.1016/j.isci.2022.105643

Figure Lengend Snippet:

Article Snippet: Human HLA Class II Histocompatibility Antigen, DR Alpha Chain (HLA-DRA) ELISA kit , Cusabio , Cat# CSB-EL010497HU.

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Protease Inhibitor, Mass Spectrometry, Generated, Software